title: Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost.
abstract: Atypical antipsychotics generally have milder side-effects than conventional antipsychotics, but also differ among themselves in this respect. This study aimed to compare the impact of different side-effect profiles of individual atypical antipsychotics on non-compliance, relapse and cost in schizophrenia. A state-transition model was built using literature data supplemented by expert opinion. The model found that quetiapine and ziprasidone were similar in estimated non-compliance and relapse rates. Olanzapine and risperidone had higher estimated non-compliance and relapse rates, and incremental, 1-year, per-patient direct costs, using US-based cost data, of approximately $530 (95% confidence interval [CI] approximately $275, $800), and approximately $485 (95% CI approximately $235, $800), respectively, compared with quetiapine. Incremental costs attributable to different side-effect profiles were highly significant. This study shows that differing side-effect profiles of the newer antipsychotic agents are likely to lead to different compliance rates, and consequent variation in relapse rates. The cost implications of these heterogenous clinical outcomes are substantial.
authors.affiliation: Department of Psychiatry, University of Hull, Willerby, Hull, UK.
authors.forename: A
authors.initials: A
authors.lastname: Mortimer
authors.forename: P
authors.initials: P
authors.lastname: Williams
authors.forename: D
authors.initials: D
authors.lastname: Meddis
mesh_terms: D014150:Antipsychotic Agents / Q000191:economics / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000191:economics / Q000627:therapeutic use*; D003987:Dibenzothiazepines / Q000191:economics / Q000627:therapeutic use; D017048:Health Care Costs; D006801:Humans; D000077152:Olanzapine; D010349:Patient Compliance; D010879:Piperazines / Q000191:economics / Q000627:therapeutic use; D000069348:Quetiapine Fumarate; D012008:Recurrence; D018967:Risperidone / Q000191:economics / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000191:economics*; D013844:Thiazoles / Q000191:economics / Q000627:therapeutic use; D006113:United Kingdom
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D010879:Piperazines; D013844:Thiazoles; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; C092292:ziprasidone; D018967:Risperidone; D000077152:Olanzapine